AI assistant
EuroAPI — Proxy Solicitation & Information Statement 2026
Apr 29, 2026
1305_rns_2026-04-29_bcee785a-7c13-4a9b-ae16-3442f03c5f96.pdf
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
euroAPI
Press Release
Paris, 29 April, 2026
Combined General Meeting of May 27, 2026
Availability of preparatory documents
EUROAPI's shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 27, 2026, at 10:00 a.m. (CET) at 15 bis, rue Traversière 75012 Paris (Théâtre Traversière).
The notice of meeting was published in the French official legal announcement publication (BALO) on Wednesday April 20, 2026 (Bulletin BALO n°48 du 22/04/2026, affaire n°2601097 | journal-officiel.gouv.fr)
The convening notice (avis de convocation) was published in the French official legal announcement publication (BALO), on April 29, 2025 (Bulletin BALO n°51 du 29/04/2026, affaire n°2601292 | journal-officiel.gouv.fr) and in lefigaro.fr, a French journal of legal notice (n° L0239073)
In accordance with the law, shareholders may consult the preparatory documents for this meeting on the Company's website in the section entitled "Annual General Meeting 2026" (Annual General Meetings | EUROAPI).
Shareholders are invited to regularly consult the Annual General Meetings section of EUROAPI's website, which will be updated with any changes regarding participation in the meeting.
About EUROAPI
EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet customers' and patients' needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are committed to building together the future of public health by advancing and securing access to essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on Euronext Paris: EAPI. Find out more at www.euroapi.com and follow us on LinkedIn.
Media Relations contact:
Laurence Bollack
Tel.: +33 (0)6 81 86 80 19
Investor Relations contact:
Sophie Palliez-Capian
Tel.: +33 (0)6 87 89 33 51
Léa Massonneau
Tel: +33 (0)7 60 32 29 50